• Advaxis cuts staff as it seeks partner for troubled cancer vaccine fiercebiotech
    June 11, 2018
    Just six weeks after taking the helm of biotech Advaxis, CEO Ken Berlin has launched a search for a partner for its stalled lead axalimogene filolisbac (AXAL) and will scale back trials of the immunotherapy in order to bring earlier stage programs forward
  • New leadership at Advaxis biospectrumasia
    April 25, 2018
  • FDA Halts Advaxis Study Following Patient Death biospace
    March 14, 2018
PharmaSources Customer Service